ELIZABETH MAPLES: Open Payments
NPI 1548298003 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,079 in 115 payments from 15 companies in 2025. Trend: 2023 $162 · 2024 $338 · 2025 $2,079
Food & beverage: $2,079
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $330 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $259 |
| Alkermes, Inc. | 13 | $230 |
| ABBVIE INC. | 17 | $230 |
| Otsuka America Pharmaceutical, Inc. | 18 | $218 |
| Lundbeck LLC | 10 | $187 |
| E.R. Squibb & Sons, L.L.C. | 10 | $179 |
| Axsome Therapeutics, Inc. | 8 | $134 |
| Vanda Pharmaceuticals Inc. | 6 | $112 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
Products named: INGREZZA, REXULTI, CAPLYTA, VRAYLAR, ARISTADA, COBENFY, Auvelity, ABILIFY ASIMTUFII.
Industry payments across TX — which companies pay providers there.
